Verfahren zur Behandlung von Krebs mit einem Bcl-2-Inhibitor in Verbindung mit einer Alpha-Emittierenden Radioimmuntherapie

Details

Veröffentlichungs-Nr.

EP4772537

Anmeldetag

26. April 2018

Veröffentlichung

8. Juli 2026

Rechtsraum

EP

IPC

C07K16/28

Abstract

This invention provides a method for treating a subject afflicted with cancer, comprising administering to the subject (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets cancer cells in the subject, wherein the amounts of the BCL-2 inhibitor and labeled agent, when administered in conjunction with one another, are therapeutically effective. This invention also provides a method for inducing the death of a cancer cell, comprising contacting the cell with (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets the cancer cell, wherein the amounts of BCL-2 inhibitor and labeled agent, when concurrently contacted with the cell, are effective to induce the cell's death.

Anmelder

Firma

Actinium Pharmaceuticals, Inc.

Land

🇺🇸 USA

Fachgebiete